Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma - PubMed (original) (raw)
Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma
Lijun Zhu et al. Mol Cancer Ther. 2005 May.
Abstract
The presence of t(4;14)(p16.3;q32.3) in multiple myeloma cells results in dysregulated expression of the fibroblast growth factor receptor 3 (FGFR3). FGFR3 acts as an oncogene to promote multiple myeloma cell proliferation and antiapoptosis. These encourage the clinical development of FGFR3-specific inhibitors. Three short hairpin RNAs (shRNA) targeting different sites of FGFR3 were selected and subsequently transfected into KMS-11, OPM-2, and NCI-H929 human myeloma cell lines, all of which are characterized by t(4;14) and FGFR3 over expression. The combination of these three shRNAs can effectively inhibit FGFR3 expression in all three cell lines. Sequential immunocytochemistry/fluorescence in situ hybridization was employed to validate that the shRNAs specifically inhibited FGFR3 expression in OPM-2 cells. Decreased expression of B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) and myeloid cell leukemia sequence 1 (MCL1) proteins and increased staining of Annexin V-positive cells showed that inhibition of FGFR3 induces apoptosis. After confirming down-regulation of FGFR3 by real-time PCR, HU-133 plus 2.0 array was employed to compare the gene expression profile of shRNA-treated sample with that of the control. Besides the down-regulation of FGFR3, expression of the antiapoptotic genes CFLAR, BCL2, MCL1, and some members of NF-kappaB family decreased, whereas expression of the proapoptotic genes CYC, BID, CASP2, and CASP6 increased. Microarray results also revealed changes in genes previously implicated in multiple myeloma pathogenesis (RAS, RAF, IL-6R, and VEGF), as well as others (TLR4, KLF4, and GADD45A) not previously linked to multiple myeloma. Our observations indicate that shRNAs can specifically and effectively inhibit FGFR3 expression. This targeted approach may be worth testing in multiple myeloma patients with t(4;14) and FGFR3 overexpression in the future.
Similar articles
- Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T, Yamada O, Yata K, Sakaguchi H, Kurebayashi J, Nakazawa N, Taniwaki M, Yawata Y, Ueki A. Otsuki T, et al. Int J Oncol. 1999 Dec;15(6):1205-12. doi: 10.3892/ijo.15.6.1205. Int J Oncol. 1999. PMID: 10568829 - Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.
Qian S, Somlo G, Zhou B, Zhu L, Mi S, Mo X, Cheung EM, Qiu W, Lin RJ, Rossi J, Holtz M, Chu P, Yen Y. Qian S, et al. Oligonucleotides. 2005 Spring;15(1):1-11. doi: 10.1089/oli.2005.15.1. Oligonucleotides. 2005. PMID: 15788896 - Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG, Stewart AK. Plowright EE, et al. Blood. 2000 Feb 1;95(3):992-8. Blood. 2000. PMID: 10648414 - The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.
Chesi M, Bergsagel PL, Kuehl WM. Chesi M, et al. Curr Opin Hematol. 2002 Jul;9(4):288-93. doi: 10.1097/00062752-200207000-00005. Curr Opin Hematol. 2002. PMID: 12042702 Review. - Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event.
Geller MD, Pei Y, Spurgeon SE, Durum C, Leeborg NJ. Geller MD, et al. Cancer Genet. 2014 Jul-Aug;207(7-8):340-3. doi: 10.1016/j.cancergen.2014.09.004. Epub 2014 Sep 19. Cancer Genet. 2014. PMID: 25441688 Review.
Cited by
- Successful application of a direct detection slide-based sequential phenotype/genotype assay using archived bone marrow smears and paraffin embedded tissue sections.
Bedell V, Forman SJ, Gaal K, Pullarkat V, Weiss LM, Slovak ML. Bedell V, et al. J Mol Diagn. 2007 Nov;9(5):589-97. doi: 10.2353/jmoldx.2007.070050. J Mol Diagn. 2007. PMID: 17975026 Free PMC article. - Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma.
Xiong S, Zhou J, Tan TK, Chung TH, Tan TZ, Toh SH, Tang NXN, Jia Y, See YX, Fullwood MJ, Sanda T, Chng WJ. Xiong S, et al. Nat Commun. 2024 Aug 9;15(1):6810. doi: 10.1038/s41467-024-50910-z. Nat Commun. 2024. PMID: 39122682 Free PMC article. - Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.
Tomlinson DC, Hurst CD, Knowles MA. Tomlinson DC, et al. Oncogene. 2007 Aug 30;26(40):5889-99. doi: 10.1038/sj.onc.1210399. Epub 2007 Mar 26. Oncogene. 2007. PMID: 17384684 Free PMC article. - Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.
Foldynova-Trantirkova S, Wilcox WR, Krejci P. Foldynova-Trantirkova S, et al. Hum Mutat. 2012 Jan;33(1):29-41. doi: 10.1002/humu.21636. Epub 2011 Nov 16. Hum Mutat. 2012. PMID: 22045636 Free PMC article. Review. - FGFR3△7-9 promotes tumor progression via the phosphorylation and destabilization of ten-eleven translocation-2 in human hepatocellular carcinoma.
Jin Z, Feng H, Liang J, Jing X, Zhao Q, Zhan L, Shen B, Cheng X, Su L, Qiu W. Jin Z, et al. Cell Death Dis. 2020 Oct 23;11(10):903. doi: 10.1038/s41419-020-03089-2. Cell Death Dis. 2020. PMID: 33097695 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous